TONGHUA GOLDEN-HORSE(000766)2025-05-28 05:40Group 1: Financial Performance and Debt Management - The company aims to gradually reduce its high debt ratio as its operational stability and profitability improve [2] - The company has not distributed dividends for 20 years, and future dividend distribution will depend on legal regulations and company policies [3] Group 2: New Drug Development and Market Potential - The new drug, HuPo BaTian Nian An Dian Pian, is designed to meet the needs of over 300 million elderly patients in China suffering from Alzheimer's disease [2] - The production system is built according to GMP standards, ensuring that it can meet domestic demand for Alzheimer's medication upon approval [4] - The drug has received acceptance for its listing application from the National Medical Products Administration, entering the review phase [3][5] Group 3: Competitive Landscape and Pricing Strategy - The company is aware of competitive products like Lecanemab and Galantamine, and is strategizing on pricing and market entry for its new drug [3] - The company emphasizes that its new drug offers significant patient benefits without increasing safety risks compared to existing treatments [8] Group 4: Intellectual Property and Regulatory Compliance - The new drug has received patent protection in multiple countries, including Japan and 15 European nations, with a U.S. patent expected by September 2024 [4] - The review process for the new drug is proceeding normally, and the company is committed to timely disclosures regarding its progress [6][7] Group 5: Future Outlook and Strategic Plans - The company plans to enhance its innovation capabilities and adjust its product structure to improve revenue growth [7] - The new drug is expected to significantly enhance the company's profitability once it is commercialized [8]